TESARO Inc  

(Public, NASDAQ:TSRO)   Watch this stock  
Find more results for MERCK SHARP & DOHME CORP
55.75
-0.99 (-1.74%)
Jul 2 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 55.57 - 57.01
52 week 23.00 - 64.97
Open 56.78
Vol / Avg. 348,856.00/407,332.00
Mkt cap 2.23B
P/E     -
Div/yield     -
EPS -4.66
Shares 40.00M
Beta 1.00
Inst. own 108%
Aug 6, 2015
Q2 2015 TESARO Inc Earnings Release - 4:00PM EDT - Add to calendar
Jun 3, 2015
TESARO Inc at Jefferies Global Healthcare Conference
May 30, 2015
TESARO Inc Investor & Analyst Briefing at ASCO - Webcast
May 14, 2015
TESARO Inc Annual Shareholders Meeting
May 6, 2015
TESARO Inc at Deutsche Bank Health Care Conference
May 5, 2015
TESARO Inc at Mizuho Securities Healthcare Corporate Access Day
May 5, 2015
TESARO Inc at Citi Midwest Healthcare Access Day
Apr 30, 2015
Q1 2015 TESARO Inc Earnings Call - Webcast
Apr 30, 2015
Q1 2015 TESARO Inc Earnings Release
Apr 15, 2015
TESARO Inc at Jefferies Immuno-Oncology Summit
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -58.04% -85.62%
Return on average equity -100.76% -138.35%
Employees 108 -
CDP Score - -

Address

1000 Winter St Ste 3300
WALTHAM, MA 02451-1230
United States - Map
+1-339-9700900 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

TESARO, Inc. (TESARO) is oncology-focused biopharmaceutical company. The Company acquires, in-licenses and develops oncology product candidates. The Company has in-licensed and are developing three clinical-stage product candidates, rolapitant, niraparib and TSR-011. Rolapitant is a potent and long-acting neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting (CINV); Niraparib, formerly known as MK-4827, is an orally active and potent poly (ADP-ribose) polymerase, and TSR-011 is an orally available targeted anti-cancer agent which is a potent inhibitor of both anaplastic lymphoma kinase (ALK) and tropomyosin-related kinase (TRK). The Company is also developing immuno-oncology programs by entering into a collaboration and exclusive license agreement with AnaptysBio, Inc., for the discovery and development of antibodies for several specified immuno-oncology targets.

Officers and directors

David M. Mott Independent Chairman of the Board
Age: 49
Bio & Compensation  - Reuters
Mary Lynne Hedley Ph.D. President, Chief Operating Officer, Director
Age: 52
Bio & Compensation  - Reuters
Leon O. Moulder Jr. Chief Executive Officer, Director
Age: 57
Bio & Compensation  - Reuters
Timothy R. Pearson Chief Financial Officer, Executive Vice President
Age: 47
Bio & Compensation  - Reuters
Joseph L. Farmer Senior Vice President, General Counsel, Secretary
Age: 43
Bio & Compensation  - Reuters
James O. Armitage M.D. Independent Director
Age: 68
Bio & Compensation  - Reuters
Garry A Nicholson Independent Director
Bio & Compensation  - Reuters
Arnold L. Oronsky Ph.D. Independent Director
Age: 75
Bio & Compensation  - Reuters
Beth C. Seidenberg M.D. Independent Director
Age: 56
Bio & Compensation  - Reuters